Disseminated intravascular coagulation

Indian Journal of Anaesthesia

Volumn 58, Issue 5, 2014, Pages 603-608

  Venugopal, A ^a  

^a REGIONAL CANCER CENTRE   (India)

Author keywords

Activated protein C; Anti thrombin; Coagulation factors; Disseminated intravascular coagulation; Fibrin degradation products; Thrombosis; Tissue factor

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 7A; FIBRINOGEN; HEPARIN; PROTEIN C;

BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD COMPONENT THERAPY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HUMAN; LABORATORY TEST; MORTALITY; PATHOGENESIS; PROTHROMBIN TIME; REVIEW; SCORING SYSTEM; SEPTICEMIA; SYSTEMIC DISEASE; THROMBOCYTOPENIA; THROMBOPLASTIN TIME;

EID: 84924965701     PISSN: 00195049     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5049.144666     Document Type: Review

References (29)

1. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-92.
2. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-30.
3. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-14.
4. Gando S. Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost 2001;27:585-92.
5. Levi M. Cancer and DIC. Haemostasis 2001;31 Suppl 1:47-8.
6. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001;102:V215-24.
7. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Büller HR, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114-20.
8. Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1997;55:169-74.
9. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996;88:881-6.
10. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001;86:51-6.
11. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001;29:S90-4.
12. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-16.
13. de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000;95:1124-9.
14. Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost 1999;82:695-705.
15. Toh CH, Dennis M. Disseminated intravascular coagulation: Old disease, new hope. BMJ 2003;327:974-7.
16. Wilde JT, Kitchen S, Kinsey S, Greaves M, Preston FE. Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. Br J Haematol 1989;71:65-70.
17. Akca S, Haji-Michael P, de Mendonça A, Suter P, Levi M, Vincent JL. Time course of platelet counts in critically ill patients. Crit Care Med 2002;30:753-6.
18. Nakamura Y, Tomura S, Tachibana K, Chida Y, Marumo F. Enhanced fibrinolytic activity during the course of hemodialysis. Clin Nephrol 1992;38:90-6.
19. Asakura H, Ontachi Y, Mizutani T, Kato M, Ito T, Saito M, et al. Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol 2001;67:170-5.
20. Downey C, Kazmi R, Toh CH. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Thromb Haemost 1998;80:65-9.
21. Matsumoto T, Wada H, Nishioka Y, Nishio M, Abe Y, Nishioka J, et al. Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation. Clin Appl Thromb Hemost 2006;12:185-92.
22. Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004;32:2416-21.
23. Sivula M, Tallgren M, Pettilä V. Modified score for disseminated intravascular coagulation in the critically ill. Intensive Care Med 2005;31:1209-14.
24. Cauchie P, Cauchie Ch, Boudjeltia KZ, Carlier E, Deschepper N, Govaerts D, et al. Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital - Meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation. Am J Hematol 2006;81:414-9.
25. Angstwurm MW, Dempfle CE, Spannagl M. New disseminated intravascular coagulation score: A useful tool to predict mortality in comparison with Acute Physiology and Chronic Health Evaluation II and Logistic Organ Dysfunction scores. Crit Care Med 2006;34:314-20.
26. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009;145:24-33.
27. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care 2006;10:222.
28. Levi M. Diagnosis and treatment of disseminated intravascular coagulation. Int J Lab Hematol 2014;36:228-36.
29. Levi M, Van Der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol 2013;79:294-8.